Patents by Inventor Sherry Ci

Sherry Ci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10800760
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 13, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Patent number: 10738033
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 11, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180346450
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180346451
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20070161601
    Abstract: Sterile, stable pharmaceutical formulations of emulsions of neat propofol or propofol dissolved in a solvent and containing no preservative are provided that comprise optimal amounts of surfactants such as lecithin and solvent such as soybean oil, with a suitable pH range to prevent significant growth of microorganisms for at least 24 hours after adventitious, extrinsic contamination. The lower amount of oil or absence (oil) in the formulation also allows chronic sedation over extended periods of time with a reduced chance of lipid overload in the blood.
    Type: Application
    Filed: May 7, 2004
    Publication date: July 12, 2007
    Applicant: American BioScience, Inc
    Inventors: Neil Desai, Andrew Yang, Tapas De, Sherry Ci, Patrick Soon-Shiong
  • Publication number: 20050009731
    Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
    Type: Application
    Filed: July 10, 2003
    Publication date: January 13, 2005
    Applicant: American BioScience, Inc.
    Inventors: Neil Desai, Andrew Yang, Sherry Ci
  • Publication number: 20050004002
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: December 9, 2003
    Publication date: January 6, 2005
    Applicant: American BioScience, Inc.
    Inventors: Neil Desai, Andrew Yang, Tapas De, Sherry Ci, Patrick Soon-Shiong, Vuong Trieu, Oiang Yao, Bridget Grim